Answers are grounded in this paper and cite their sources.
BACKGROUND Patients with suspicious pulmonary lesions are traditionally rejected or delisted for lung transplantation (LTx). Data on the overall prevalence of suspicious lung lesions in candidates for LTx, their characteristics and the actual proportion of malignancy among these lesions is lacking. METHODS We performed a retrospective analysis of all patients with suspicious lung nodules who underwent lung transplantation between 01/2012 and 10/2022. We compared characteristics of lesions, assessed definitive histology reports and analyzed postoperative outcomes using 1:4 propensity score matching and calculated overall survival at 1-, 3-, and 5-years. RESULTS Out of 1070 transplanted patients, 79 (7.4%) had suspicious lung lesions prior to LTx. In this group, COPD was the most frequent indication for LTx (83.5% of patients). The median age at LTx in the ‘pulmonary lesions' group was significantly higher than in patients without lesions (median 61, IQR 57 - 64 vs median 54 (IQR 37 – 61) years; p=<0.001). Pathology reports confirmed lung cancer in explanted native lungs in only 12 of the 79 patients (15.1%). The most common lung cancer entity was adenocarcinoma in 8 patients (66.7%), followed by giant cell carcinoma of the lung in 2 patients (16.6%), and squamous cell carcinoma in 2 patients (16.6%). Ten of the 12 (83.3%) patients were in stage I, II and 2 (16.6%) patients were in stage-IIIA disease based on final histological work-up after LTx. Overall survival did not differ between ‘malignant nodules' subgroup, ‘non-malignant nodules' subgroup and their respective matched controls at 1 year (87.5% vs 89.7% vs 88.2%), 3 years (87.5% vs 78.6% vs 77.5%) or 5 years (87.5% vs 70.1% vs 68.6%) (cox proportional-hazards model, p=0.541). CONCLUSION Patients with unverified suspicious lung lesions should not be excluded from LTx, as only a small proportion of these nodules are malignant. Long-term survival is unaffected even in cases the explanted lung harbors an early-stage lung cancer.
No takes yet. Share an insight, caveat, or question.
Begic et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: